Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TI-0032-III
- Development stage
- Phase 1
- Lead developer
- Therorna
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
TI-0032-III is an investigational in vivo CAR-T cell therapy developed by Therorna for the treatment of relapsed and refractory B cell-mediated autoimmune diseases. The therapeutic product consists of lipid nanoparticles (LNPs) that target T cells and encapsulate circular RNA (circRNA) encoding a CD19-specific chimeric antigen receptor (CAR). Unlike traditional ex vivo CAR-T therapies that require complex cell manufacturing outside the body, TI-0032-III is designed to reprogram T cells directly within the patient's body to identify and deplete pathogenic B cells. This approach aims to provide a more scalable and accessible treatment for various autoimmune conditions, including systemic lupus erythematosus (SLE), Sjögren's syndrome, and systemic sclerosis.
- Other names
- TI-0032-III injectionTI0032-III injectionTI 0032-III injection
02
Targets
Beyond the preview
Go deeper on TI-0032-III.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TI-0032-III.